XAIR — Beyond Air Inc
NASDAQ · Healthcare · Medical Devices
$4.98
+$0.07 (+1.43%)
Beyond Air Inc (XAIR) is a medical devices company listed on NASDAQ. It is led by Steven Adam Lisi, based in 900 Stewart Avenue, Garden City, NY, United States, 11530, with about 61 employees. Beyond Air, Inc., a commercial-stage medical device and biopharmaceutical company, develops the Lungfit platform, a nitric oxide (NO) generator and delivery system platform. It operates through three segments: Beyond Air, Beyond Cancer, and NeuroNos. The company offers Lungfit PH for the treatment of persistent pulmonary hypertension of the newborn. It is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired pneumonia, including COVID-19 and bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria (NTM) at home. In addition, the company develops ultra-high concentration (UNO) that is in Phase 1 clinical trial to treat multiple solid and cutaneous tumors; and selective neuronal nitric oxide synthase (nNOS) inhibitor for the treatment of neurological conditions and autism spectrum disorder. It has a collaboration with the Yissum Research Development Company of the Hebrew University of Jerusalem, LTD to acquire the commercial rights for neuronal nitric oxide synthase inhibitors to treat autism spectrum disorder and other neurological conditions. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. was founded in 2011 and is headquartered in Garden City, New York.
Latest reported XAIR revenue for 2025-09-30 was $1.8M. Net income was -$8.3M. Revenue was up 3.3% from 2025-06-30 to 2025-09-30. XAIR currently screens at market cap $16.0M.
Use this XAIR page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the XAIR quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the XAIR SEC filings page. Lician reads the product cache first so this HTML stays unique to Beyond Air Inc even when a live quote feed is slow.
About Beyond Air Inc
Beyond Air, Inc., a commercial-stage medical device and biopharmaceutical company, develops the Lungfit platform, a nitric oxide (NO) generator and delivery system platform. It operates through three segments: Beyond Air, Beyond Cancer, and NeuroNos. The company offers Lungfit PH for the treatment of persistent pulmonary hypertension of the newborn. It is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired pneumonia, including COVID-19 and bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria (NTM) at home. In addition, the company develops ultra-high concentration (UNO) that is in Phase 1 clinical trial to treat multiple solid and cutaneous tumors; and selective neuronal nitric oxide synthase (nNOS) inhibitor for the treatment of neurological conditions and autism spectrum disorder. It has a collaboration with the Yissum Research Development Company of the Hebrew University of Jerusalem, LTD to acquire the commercial rights for neuronal nitric oxide synthase inhibitors to treat autism spectrum disorder and other neurological conditions. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. was founded in 2011 and is headquartered in Garden City, New York.
XAIR Key Statistics
Market Cap
$15.99M
Volume
289,241
Previous Close
$4.91
Day Range
$4.41 – $5.06
EPS
-$0.69
Revenue
$3.71M
Net Income
-$48.48M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
+219.7%
Profit Margin
-1308.5%
Employees
61
XAIR Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | $3.71M | $1.16M | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$48.48M | -$64.30M | -$59.40M | -$44.06M |
| EPS (Diluted) | -$0.69 | -$1.82 | -$1.86 | $0.00 |
Total Assets
$30.06M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$4.67M
Operating Cash Flow
-$38.22M
Free Cash Flow
$0.00
Beyond Air Inc Company Information
- CEO & Chairman of the Board
- Steven Adam Lisi
- Headquarters
- 900 Stewart Avenue, Garden City, NY, United States, 11530
- Website
- www.beyondair.net
- Phone
- 516 665 8200
- IPO / Founded
- 2017-09-22
- Sector
- Healthcare
- Industry
- Medical Devices